Profil
Lynn Connolly occupe le poste de directeur médical chez Adagio Therapeutics, Inc. Dans sa carrière antérieure, elle a été directrice médicale principale chez Achaogen, Inc. et vice-présidente de Vir Biotechnology, Inc. Le Dr. Connolly a obtenu un diplôme de premier cycle à l'Université de Californie, Berkeley et un doctorat à l'Université de Californie, San Francisco.
Anciens postes connus de Lynn Connolly
| Sociétés | Poste | Fin |
|---|---|---|
| INVIVYD, INC. | Chief Tech/Sci/R&D Officer | 25/03/2022 |
| VIR BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 01/07/2020 |
| ACHAOGEN | Chief Tech/Sci/R&D Officer | 01/01/2017 |
Formation de Lynn Connolly
| University of California, Berkeley | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VIR BIOTECHNOLOGY, INC. | Health Technology |
| INVIVYD, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
